Luigi di Nuzzo, Rosamaria Orlando, Cristina Tognoli, Paola Di Pietro, Giuseppe Bertini, Jessica Miele, Domenico Bucci, Marta Motolese, Sergio Scaccianoce, Alessandra Caruso, Gianluca Mauro, Carmine De Lucia, Giuseppe Battaglia, Valeria Bruno, Paolo Francesco Fabene, Ferdinando Nicoletti
Recent findings indicate that fingolimod, the first oral drug approved for the treatment of multiple sclerosis (MS), acts as a direct inhibitor of histone deacetylases (HDACs) and enhances the production of brain-derived neurotrophic factor (BDNF) in the CNS. Both mechanisms are relevant to the pathophysiology and treatment of major depression. We examined the antidepressant activity of fingolimod in mice subjected to chronic unpredictable stress (CUS), a model of reactive depression endowed with face and pharmacological validity...
June 2015: Pharmacology Research & Perspectives